MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE

被引：0
|
作者：
Benettaib, B. [1 ]
Lee, D. [2 ]
Dhanasiri, S. [3 ]
Brereton, N. [2 ]
机构：
[1] Sarl, Celgene Int, Geneva, Switzerland
[2] BresMed, Sheffield, S Yorkshire, England
[3] Celgene Ltd, Uxbridge, Middx, England
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P740
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [21] Cytopenias correlate with response to lenalidomide in del 5q MDS patients
    Sekeres, M. A.
    Maciejewski, J. P.
    Giagounidis, A.
    Wride, K.
    Knight, R.
    List, A.
    LEUKEMIA RESEARCH, 2007, 31 : S37 - S38
  • [22] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
  • [23] Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
    Komrokji, R. S.
    List, A. F.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 62 - 68
  • [24] Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities.
    Raza, Azra
    Reeves, James E.
    Feldman, Eric J.
    Deeg, H. Joachim
    Dreisbach, Luke
    Schiffer, Charles A.
    Shammo, Jamile M.
    Klimek, Virginia M.
    Greenberg, Peter L.
    Bennett, John M.
    DeWald, Gordon W.
    Zeldis, Jerome B.
    Wride, Kenton
    Schmidt, Michele
    Knight, Robert D.
    List, Alan F.
    BLOOD, 2006, 108 (11) : 78A - 78A
  • [25] Long-Term Response in a Patient with del (5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
    Pisani, Francesco
    Orlandi, Giulia
    Merola, Roberta
    CASE REPORTS IN ONCOLOGY, 2014, 7 (01): : 277 - 284
  • [26] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [27] LENALIDOMIDE (LEN) IN MYELODYSPLASTIC (MDS) DEL(5Q) PATIENTS: A SINGLE INSTITUTION POPULATION-BASED EXPERIENCE
    Pelizzari, A.
    Cerqui, E.
    Schieppati, F.
    Borlenghi, E.
    Pagani, C.
    Bellotti, D.
    Rossi, G.
    HAEMATOLOGICA, 2013, 98 : 580 - 580
  • [28] Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
    Gurnari, Carmelo
    Piciocchi, Alfonso
    Soddu, Stefano
    Bonanni, Fabrizio
    Scalzulli, Emilia
    Niscola, Pasquale
    Di Veroli, Ambra
    Piccioni, Anna Lina
    Piedimonte, Monica
    Maiorana, Gianluca
    Salutari, Prassede
    Cicconi, Laura
    Santopietro, Michelina
    Gumenyuk, Svitlana
    Sarlo, Chiara
    Fenu, Susanna
    Tafuri, Agostino
    Latagliata, Roberto
    Fianchi, Luana
    Criscuolo, Marianna
    Maciejewski, Jaroslaw P.
    Maurillo, Luca
    Buccisano, Francesco
    Breccia, Massimo
    Voso, Maria Teresa
    BLOOD CANCER JOURNAL, 2022, 12 (09)
  • [29] Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
    Carmelo Gurnari
    Alfonso Piciocchi
    Stefano Soddu
    Fabrizio Bonanni
    Emilia Scalzulli
    Pasquale Niscola
    Ambra Di Veroli
    Anna Lina Piccioni
    Monica Piedimonte
    Gianluca Maiorana
    Prassede Salutari
    Laura Cicconi
    Michelina Santopietro
    Svitlana Gumenyuk
    Chiara Sarlo
    Susanna Fenu
    Agostino Tafuri
    Roberto Latagliata
    Luana Fianchi
    Marianna Criscuolo
    Jaroslaw P. Maciejewski
    Luca Maurillo
    Francesco Buccisano
    Massimo Breccia
    Maria Teresa Voso
    Blood Cancer Journal, 12
  • [30] Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide
    Follo, M. Y.
    Mongiorgi, S.
    Clissa, C.
    Stoyanova, M.
    Paolini, S.
    Quaranta, M.
    Martinelli, G.
    Manzoli, L.
    Cocco, C.
    Finelli, C.
    LEUKEMIA RESEARCH, 2013, 37 : S28 - S28
12345